Evidence map›Paper›PMID 33159172›Full record

Trial reportScientific reports2020

Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Giandomenico Roviello, Monica Ramello, Martina Catalano, Alberto D'Angelo, Raffaele Conca, Silvia Gasperoni, Lorenzo Dreoni, Roberto Petrioli, Anna Ianza, Stefania Nobili and 2 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Understanding the Conundrum of Pancreatic Cancer in the Omics Sciences Era.International journal of molecular sciences · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Giandomenico RovielloDepartment of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy. giandomenicoroviello@hotmail.it.
Monica RamelloOncology Unit, Department of Medical, Surgical, and Health Sciences, University of Trieste, Piazza Ospitale, Trieste, Italy.
Martina CatalanoSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Alberto D'AngeloDepartment of Biology and Biochemistry, University of Bath, Bath, BA2 7AY, UK.
Raffaele ConcaDivision of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, via Padre Pio 1, 85028, Rionero, Vulture, PZ, Italy.
Silvia GasperoniTranslational Oncology Unit, University Hospital Careggi, Firenze, Toscana, Italy.
Lorenzo DreoniSchool of Human Health Sciences, University of Florence, Largo Brambilla 3, 50134, Florence, Italy.
Roberto PetrioliDepartment of Medicine, Surgery and Neurosciences, Medical Oncology Unit, University of Siena, Viale Bracci-Policlinico "Le Scotte", 53100, Siena, Italy.
Anna IanzaOncology Unit, Department of Medical, Surgical, and Health Sciences, University of Trieste, Piazza Ospitale, Trieste, Italy.
Stefania NobiliDepartment of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
Michele AietaDivision of Medical Oncology, Department of Onco-Hematology, IRCCS-CROB, Referral Cancer Center of Basilicata, via Padre Pio 1, 85028, Rionero, Vulture, PZ, Italy.
Enrico MiniDepartment of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy.
University of Florence · ITUniversity of Trieste · ITAzienda Ospedaliero-Universitaria Careggi · ITCentro di Riferimento Oncologico della Basilicata · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bath · GBUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutropenia is a common side effect associated with nab-paclitaxel gemcitabine (Nab-Gem) therapy. We retrospectively investigated the association between neutropenia induced by first-line Nab-Gem and survival in metastatic pancreatic carcinoma patients. Metastatic pancreatic patients treated with first-line Nab-Gem were included in this retrospective analysis. Neutropenia was categorized using the National Cancer Institute Common Toxicity Criteria scale. Outcome measures were overall survival (OS), progression-free survival (PFS) and response rate. 115 patients were analyzed. Median PFS was 7 months (95% CI 5-8) for patients with grade ≥ 3 neutropenia and 6 months (95% CI 5-6) for patients with grade < 3 neutropenia [p = 0.08; hazard ratio (HR 0.68)]. Median OS was 13 months (95% CI 10-18) for patients with grade ≥ 3 neutropenia and 10 months (95% CI 8-13) for patients with grade < 3 neutropenia (p = 0.04; HR 0.44). In multivariate analysis, the occurrence of grade ≥ 3 neutropenia showed a statistically significant association with OS (HR 0.62; 95% CI 0.09-0.86; p = 0.05). Nab-Gem-induced neutropenia is associated with longer survival in metastatic pancreatic cancer patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsNeutropeniaPancreatic NeoplasmsAgedAged, 80 and overAlbuminsDeoxycytidineDisease-Free SurvivalFemaleGemcitabineHumansMaleMiddle AgedNeoplasm MetastasisPaclitaxelRetrospective Studies130-nm albumin-bound paclitaxelAlbuminsDeoxycytidineGemcitabinePaclitaxel

Identifiers

PMID33159172
PMCPMC7648798
OpenAlexW3096053571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.